BRAF testing is currently recommended by both the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) guidelines for advanced melanoma patients [16,17]; the BRAF V600 mutation must be detected by using an FDA-approved (USA) or CE-IVD-certified (Europe) test [17,18,19]. Here, BRAF is linked to melanoma.